In the past three months, five analysts have shared their ratings on Puma Biotechnology PBYI, offering outlooks ranging from bullish to bearish.
The following table summarizes recent ratings and gives a glimpse into how sentiment has changed over the past 30 days and compares it to the previous month.
Bullish Slightly Bullish Indifferent Slightly Bearish Bearish Total Rating 5 0 0 0 0 Last 30 days 1 0 0 0 0 1 month ago 0 0 0 0 0 2 months ago 2 0 0 0 0 3 months ago 2 0 0 0 0
The 12-month price targets assessed by analysts reveal further insights with an average target of $7.0, a high forecast of $7.00 and a low forecast of $7.00. The average price target has remained unchanged, which reflects the consistent view of the analysts.
Understanding analyst ratings: A comprehensive analysis
A comprehensive look at how financial experts perceive Puma Biotechnology can be gleaned from recent analyst action. Below is a detailed summary of the key analysts, their recent valuations, and adjustments to their ratings and target prices.
Analyst Analyst Firm Action Taken Rating Current Target Price Previous Target Price Edward White HC Wainwright & Co. Maintain Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintain Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintain Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintain Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintain Buy $7.00 $7.00
Key insights:
Actions: Analysts frequently update their recommendations based on changing market conditions and company performance. Whether an analyst’s stance is “hold”, “upgrade” or “downgrade”, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the company’s current situation. Ratings: Analysts gain insight and provide qualitative ratings ranging from “outperform” to “underperform”. These ratings reflect expectations for Puma Biotechnology’s relative performance compared to the broader market. Price Targets: Analysts gain insight and provide estimates of the future value of Puma Biotechnology’s shares. This comparison reveals trends in analyst expectations over time.
Consider these analysts’ ratings along with other financial metrics to get a comprehensive understanding of Puma Biotechnology’s market position. Use our rating table to stay informed and make an informed decision.
Stay up to date with analyst ratings for Puma Biotechnology.
If you’re interested in tracking small cap news and performance, start here.
What you need to know about Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products that enhance cancer care and improve patient outcomes. The company is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. The company is also developing alisertib, a selective small molecule inhibitor of Aurora kinase A designed to block mitosis and induce apoptosis in rapidly proliferating tumor cells that are dependent on Aurora kinase A.
A closer look at Puma Biotechnology’s financial situation
Market Cap: The company’s market cap, which is above the industry norm, asserts a size advantage and suggests a solid market position.
Revenue Challenges: Puma Biotechnology’s three-month revenue growth has faced challenges. As of March 31, 2024, the company experienced a decline of about -17.07%, which indicates a decline in sales. Compared to its industry peers, the company is lagging behind with a lower growth rate than the average of its healthcare sector peers.
Net Profit Margins: Puma Biotechnology’s financial strength is reflected in its outstanding net profit margins, which are above the industry average. With an impressive net profit margin of -11.0%, the company boasts high profitability and effective cost management.
Return on Equity (ROE): Puma Biotechnology’s ROE is outstanding and above the industry average. With an impressive ROE of -9.22%, the company demonstrates effective utilization of equity capital and strong financial performance.
Return on Assets (ROA): Puma Biotechnology’s ROA is above the industry benchmark at -2.17%, implying efficient management of assets and strong financial health.
Debt Management: Puma Biotechnology’s debt-to-equity ratio is significantly higher than the industry average. The ratio is 2.17, which indicates that the company is highly dependent on borrowings and has a high level of financial risk.
Understanding the relevance of analyst ratings
Benzinga tracks 150 analyst firms and reports on stock forecasts. Analysts typically draw their conclusions by forecasting how much profit a company will make in the future (usually the next five years) and how risky or predictable the company’s revenue streams are.
Analysts attend company conference calls and meetings, study company financial statements, communicate with insiders, and issue their ratings on stocks. Analysts typically rate each stock once per quarter, or whenever there is a major update on the company.
Some analysts also issue forecasts for metrics such as growth projections, earnings, and revenue, providing additional guidance on valuation. When using analyst ratings, it is important to remember that stock and sector analysts are human and are only providing opinions to investors.
If you want to track which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro .
This article was generated by Benzinga’s automated content engine and has been reviewed by an editor.
Market news and data provided by Benzinga API
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
